Diamondback 360 Coronary Orbital Atherectomy System; Diamondback 360 Precision Coronary Orbital Atherectomy System
Cardiovascular Systems, Inc. · Decision date Feb 26, 2026
What did the FDA decide?
FDA records P130005/S050 as a supplement to PMA P130005, with the supplement type “30-Day Notice”. The recorded decision is OK30 (30-day notice), dated Feb 26, 2026.
FDA approval order statement
the addition of in-house microbiology product testing site and aligning microbiology product testing frequency to current product testing program
- Regulatory pathway
- PMA supplement
- Supplement type
- 30-Day Notice
- Clinical specialty
- Cardiovascular
- Decision date
- Feb 26, 2026
- FDA change category
- Process Change - Manufacturer/Sterilizer/Packager/Supplier
Regulatory record facts
- Identifier
- P130005/S050
- Regulatory pathway
- PMA supplement
- Applicant
- Cardiovascular Systems, Inc.
- Product code
- MCX
- Decision code
- OK30
- Decision date
- Feb 26, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: CATHETER, CORONARY, ATHERECTOMY.
- Applicant
- Cardiovascular Systems, Inc.
- Product code
- MCX
- FDA device class
- 3
Review the original FDA PMA listing for the original approval scope and linked supplements.
FDA decision timeline
P130005/S048 · Related supplement
Diamondback 360 Coronary Orbital Atherectomy System; Diamondback 360 Precision Coronary Orbital Atherectomy System
P130005/S050 received
Application receipt date recorded by FDA.
P130005/S049 · Related supplement
DIAMONDBACK 360 CORONARY ORBITAL ATHERECTOMY SYSTEM
P130005/S050 · FDA decision
30-Day Notice
P130005/S051 · Related supplement
Diamondback 360 Coronary Orbital Atherectomy System; Diamondback 360 Precision Coronary Orbital Atherectomy System
Timeline entries are records held by MedtechLedger for P130005. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P130005
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| Cardiovascular Systems, Inc. | PMA supplement | Jan 14, 2026 | FDA | |
| Cardiovascular Systems, Inc. | PMA supplement | Feb 18, 2026 | FDA | |
| Cardiovascular Systems, Inc. | PMA supplement | Mar 10, 2026 | FDA |
Explore the linked device profile
Other records with product code MCX
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
ROTAPRO Rotational Atherectomy SystemsP900056/S226 | Boston Scientific Corp | PMA supplement | Oct 21, 2026 | FDA |
ROTAPRO Rotational Atherectomy SystemP900056/S229 | Boston Scientific Corp | PMA supplement | Oct 21, 2026 | FDA |
ROTAPRO Rotational Atherectomy SystemP900056/S228 | Boston Scientific Corp | PMA supplement | Oct 20, 2026 | FDA |
ROTABLATOR Rotational Atherectomy SystemP900056/S225 | Boston Scientific Corp | PMA supplement | May 6, 2026 | FDA |
| Boston Scientific Corp | PMA supplement | Apr 9, 2026 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Cardiovascular Systems, Inc.
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- 651 Campus Dr., Minneapolis, MN, 55211
Sources and methodology
- Original FDA record: P130005/S050
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 20, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records



